Antibiotic resistance of Escherichia coli from outpatient urinary tract infection in women in six European countries including Russia



: Ny Sofia, Edquist Petra, Dumpis Uga, Gröndahl-Yli-Hannuksela Kirsi, Hermes Julia, Kling Anna-Maria, Klingeberg Anja, Kozlov Roman, Källman Owe, Lis Danuta O., Pomorska-Wesołowska Monika, Saule Māra, Tegmark Wisell Karin, Vuopio Jaana, Palagin Ivan

Publisher: Elsevier

: 2019

: Journal of Global Antimicrobial Resistance

: Journal of global antimicrobial resistance

: J Glob Antimicrob Resist

: 17

: 25

: 34

: 10

: 2213-7165

: 2213-7173

DOI: https://doi.org/10.1016/j.jgar.2018.11.004

: https://www.sciencedirect.com/science/article/pii/S2213716518302200

: https://research.utu.fi/converis/portal/detail/Publication/39495128


In the Northern Dimension Antibiotic Resistance Study Finland, Germany, Latvia, Poland, Russia and Sweden investigated the resistance levels of Escherichia coli (E. coli) isolated from urine of outpatient women (18-65 years) that had symptoms of uncomplicated UTI by collecting samples in each respective nation.\nOverall antibiotic resistance (ABR) rates to certain commonly used antibiotics, such as nitrofurantoin, fosfomycin and mecillinam were 1.2%, 1.3% and 4.1% (except for Germany that was missing result for mecillinam). Highest overall resistance rates were determined for ampicillin - 39.6%, trimethoprim -23.8%, trimethoprim/sulfamethoxazole -22.4%, amoxillin/clavulanic acid - 16.7% and ciprofloxacin - 15.1%, varying significantly among the countries. ESBL-production level was 8.7%. None of the isolates showed resistance to meropenem.\nIn total 775 E. coli isolates from 1278 clinical urinary samples were collected from October 2015-January 2017. Susceptibility testing was performed and results were interpreted according to the EUCAST criteria.\nIn most cases, low ABR rates were detected against the first line antibiotics recommended in national UTI treatment guidelines which give support to their future use. Our results also support the European Association of Urology guidelines stating that nitrofurantoin, fosfomycin and mecillinam are viable treatment options for uncomplicated UTI.\nOBJECTIVES\nRESULTS\nMETHODS\nCONCLUSIONS

Last updated on 2024-26-11 at 12:34